<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37961239</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Dec</Month><Day>29</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.10.24.23297114</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.10.24.23297114</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Persistent symptoms among some persons who develop COVID-19 has led to the hypothesis that SARS-CoV-2 may, in some form or location, persist for long periods following acute infection. Several studies have shown data in this regard but are limited by non-representative and small study populations, short duration since acute infection, and lack of a true-negative comparator group to assess assay specificity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated adults with RNA-confirmed COVID-19 at multiple time points following acute infection (pandemic-era participants) and adults with specimens collected prior to 2020 (pre-pandemic era). Using once-thawed plasma, we employed the Simoa<sup>&#xae;</sup> (Quanterix) single molecule array detection platform to measure SARS-CoV-2 spike, S1, and nucleocapsid antigens.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to 250 pre-pandemic participants who had 2% assay positivity, detection of any SARS-CoV-2 antigen was significantly more frequent among 171 pandemic-era participants at three different time periods in the post-acute phase of infection. The absolute difference in SARS-CoV-2 plasma antigen prevalence was +11% (95% CI: +5.0% to +16%) at 3.0-6.0 months post-onset of COVID-19; +8.7% (95% CI: +3.1% to +14%) at 6.1 to 10.0 months; and +5.4% (95% CI: +0.42% to +10%) at 10.1-14.1 months. Hospitalization for acute COVID-19 and, among the non-hospitalized, worse self-reported health during acute COVID-19 were associated with greater post-acute phase antigen detection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared to uninfected persons, there is an excess prevalence of SARS-CoV-2 antigenemia in SARS-CoV-2-infected individuals up to 14 months after acute COVID-19. These findings motivate an urgent research agenda regarding the short-term and long-term clinical manifestations of this viral persistence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-0585-6230</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swank</LastName><ForeName>Zoe N</ForeName><Initials>ZN</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Brigham &amp; Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalhuisen</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borberg</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Brigham &amp; Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senussi</LastName><ForeName>Yasmeen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Brigham &amp; Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Celina Chang</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Alexus</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamora</LastName><ForeName>Andhy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lew</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Badri</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6425-681X</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anglin</LastName><ForeName>Khamal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscila Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-7612-3352</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glidden</LastName><ForeName>David V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel Kelly</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0001-6371-747X</Identifier><AffiliationInfo><Affiliation>Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walt</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-5524-7348</Identifier><AffiliationInfo><Affiliation>Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Brigham &amp; Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><Identifier Source="ORCID">0000-0002-9773-3256</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI134327</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167648</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Lancet Infect Dis. 2024 Jun;24(6):e345-e347. doi: 10.1016/S1473-3099(24)00211-1</RefSource><PMID Version="1">38604216</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">antigen</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">viral persistence</Keyword></KeywordList><CoiStatement>Conflicts of Interest MJP reports consulting for Gilead Sciences and AstraZeneca, outside the submitted work. DRW has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company, and also serves on its Board of Directors. Dr. Walt&#x2019;s interests were reviewed and are managed by Mass General Brigham and Harvard University in accordance with their conflict-of-interest policies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>14</Day><Hour>3</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37961239</ArticleId><ArticleId IdType="pmc">PMC10635183</ArticleId><ArticleId IdType="doi">10.1101/2023.10.24.23297114</ArticleId><ArticleId IdType="pii">2023.10.24.23297114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen X, Zhu B, Hong W, et al. Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. Int J Infect Dis 2020;98:252&#x2013;260. (In eng). DOI: 10.1016/j.ijid.2020.06.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.06.091</ArticleId><ArticleId IdType="pmc">PMC7326382</ArticleId><ArticleId IdType="pubmed">32619760</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmy T, Tsur A, Shabtay O. Duration of SARS-CoV-2 detection in Israel Defense Forces soldiers with mild COVID-19. J Med Virol 2021;93(2):608&#x2013;610. (In eng). DOI: 10.1002/jmv.26374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26374</ArticleId><ArticleId IdType="pubmed">33196120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Hang X, Wei B, et al. Persistent SARS-COV-2 RNA positivity in a patient for 92 days after disease onset: A case report. Medicine (Baltimore) 2020;99(34):e21865. (In eng). DOI: 10.1097/md.0000000000021865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000021865</ArticleId><ArticleId IdType="pmc">PMC7447437</ArticleId><ArticleId IdType="pubmed">32846839</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Xiao J, Sun R, et al. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg Infect Dis 2020;26(8):1834&#x2013;1838. (In eng). DOI: 10.3201/eid2608.201097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Owusu D, Pomeroy MA, Lewis NM, et al. Persistent SARS-CoV-2 RNA Shedding Without Evidence of Infectiousness: A Cohort Study of Individuals With COVID-19. J Infect Dis 2021;224(8):1362&#x2013;1371. (In eng). DOI: 10.1093/infdis/jiab107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab107</ArticleId><ArticleId IdType="pmc">PMC7989388</ArticleId><ArticleId IdType="pubmed">33649773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-m Hwang YJ, Kwak Y. Prolonged SARS-CoV-2 detection and reversed RT-PCR results in mild or asymptomatic patients. Infectious Diseases 2021;53(1):31&#x2013;37. DOI: 10.1080/23744235.2020.1820076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2020.1820076</ArticleId><ArticleId IdType="pubmed">32935628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2021;2(1):e13&#x2013;e22. (In eng). DOI: 10.1016/s2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat Immunol 2023;24(10):1616&#x2013;1627. DOI: 10.1038/s41590-023-01601-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01601-2</ArticleId><ArticleId IdType="pubmed">37667052</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021. DOI: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 2022;612(7941):758&#x2013;763. DOI: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Ryder D, Flavell R, et al. Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19. medRxiv 2023. DOI: 10.1101/2023.07.27.23293177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.07.27.23293177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology 2022;163(2):495&#x2013;506.e8. DOI: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis 2022. DOI: 10.1093/cid/ciac722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanberg N, Grahn A, Stentoft E, et al. COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients With Neurocognitive Post-COVID Complications. The Journal of Infectious Diseases 2023. DOI: 10.1093/infdis/jiad395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad395</ArticleId><ArticleId IdType="pmc">PMC10873166</ArticleId><ArticleId IdType="pubmed">37874918</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C, Willscher E, Paschold L, et al. Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. J Med Virol 2023;95(1):e28364. (In eng). DOI: 10.1002/jmv.28364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28364</ArticleId><ArticleId IdType="pmc">PMC9878213</ArticleId><ArticleId IdType="pubmed">36458566</ArticleId></ArticleIdList></Reference><Reference><Citation>Craddock V, Mahajan A, Spikes L, et al. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol 2023;95(2):e28568. DOI: 10.1002/jmv.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28568</ArticleId><ArticleId IdType="pmc">PMC10048846</ArticleId><ArticleId IdType="pubmed">36756925</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Kelly JD, Lu S, et al. Persistence, magnitude, and patterns of postacute symptoms and quality of life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement. Open forum infectious diseases 2022:ofab640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Milutinovic MD, Walt DR. Single molecule array (Simoa) assay with optimal antibody pairs for cytokine detection in human serum samples. Analyst 2015;140(18):6277&#x2013;6282. (10.1039/C5AN01238D). DOI: 10.1039/C5AN01238D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5AN01238D</ArticleId><ArticleId IdType="pubmed">26270328</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023;21(3):133&#x2013;146. DOI: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipar A, Meli ML, Baptiste KE, Bowker LJ, Lutz H. Sites of feline coronavirus persistence in healthy cats. J Gen Virol 2010;91(Pt 7):1698&#x2013;707. (In eng). DOI: 10.1099/vir.0.020214-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.020214-0</ArticleId><ArticleId IdType="pubmed">20237226</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel L, Van der Lubben M, te Lintelo EG, et al. Pathogenic characteristics of persistent feline enteric coronavirus infection in cats. Vet Res 2010;41(5):71. (In eng). DOI: 10.1051/vetres/2010043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/vetres/2010043</ArticleId><ArticleId IdType="pmc">PMC2939696</ArticleId><ArticleId IdType="pubmed">20663472</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt A, Singh M, Stein S, Soherwardi S, de Wit E, Chertow DS. Replication-Competent Virus Detected in Blood of a Fatal COVID-19 Case. Annals of Internal Medicine 2023. DOI: 10.7326/L23-0253.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/L23-0253</ArticleId><ArticleId IdType="pmc">PMC10714275</ArticleId><ArticleId IdType="pubmed">38079637</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Kobayashi T, Suzuki H, et al. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: A systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol 2022;2(1):e192. (In eng). DOI: 10.1017/ash.2022.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/ash.2022.336</ArticleId><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="pubmed">36505947</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ 2023;381:e074572. DOI: 10.1136/bmj-2022-074572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074572</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post&#x2013;COVID-19 Condition. JAMA Intern Med 2023. DOI: 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Dougan TJ, Walt DR. High-Throughput, High-Multiplex Digital Protein Detection with Attomolar Sensitivity. ACS Nano 2022;16(1):1025&#x2013;1035. (In eng). DOI: 10.1021/acsnano.1c08675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.1c08675</ArticleId><ArticleId IdType="pmc">PMC9499451</ArticleId><ArticleId IdType="pubmed">35029381</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway. eLife 2021;10:e68563. DOI: 10.7554/eLife.68563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68563</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang S, Bao C, Yang Z, et al. SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy. Signal Transduction and Targeted Therapy 2023;8(1):108. DOI: 10.1038/s41392-023-01368-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01368-w</ArticleId><ArticleId IdType="pmc">PMC9998025</ArticleId><ArticleId IdType="pubmed">36894537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu JK, Sozmen EG, Dixit K, et al. SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. bioRxiv 2021. DOI: 10.1101/2021.10.12.464152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.12.464152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>